Elon Musk, chief executive officer of Tesla Inc., during a fireside discussion on artificial intelligence risks with Rishi Sunak, UK prime minister, not pictured, in London, UK, on Thursday, Nov. 2, 2023.
Tolga Akmen | Bloomberg | Getty Images
Tesla and SpaceX CEO Elon Musk, who also owns the social network X (formerly known as Twitter), said Monday that he wants about 25% of voting control over his electric vehicle business.
Musk already owns around 13% of Tesla, or approximately 411 million shares of the company’s 3.19 billion shares in common stock outstanding, as reported in the company’s last financial filing for the third quarter of 2023.
Now, Musk is angling for even more control over Tesla.
Specifically, Musk wrote on Monday, “I am uncomfortable growing Tesla to be a leader in AI & robotics without having ~25% voting control. Enough to be influential, but not so much that I can’t be overturned.”
“Unless that is the case, I would prefer to build products outside of Tesla,” the billionaire executive said on X.
“You don’t seem to understand that Tesla is not one startup, but a dozen. Simply look at the delta between what Tesla does and GM. As for stock ownership itself being enough motivation, Fidelity and other own similar stakes to me. Why don’t they show up for work?”
Tesla did not immediately respond to a request for comment.
Musk’s post stood at odds with remarks he previously made suggesting Tesla is already an important AI and robotics company, and its value hinges on its prowess in these domains.
Tesla unveiled an early Optimus prototype at Tesla AI Day in September that year, and Musk said in a post around that event: “The point of AI Day is to show the immense depth & breadth of Tesla in AI, compute hardware & robotics.”
More recently, on Dec. 27, 2023, Musk criticized Roth Capital senior research analyst Craig Irwin who appeared on CNBC’s Closing Bell Overtime, saying he thought Tesla was “egregiously overvalued,” especially compared to Japanese autos giant Toyota.
Bristling at the comparison to a large competitor that has sold more hybrid electric vehicles than battery electric models, Musk said in a post on X, “He has the wrong frame of reference. Tesla is an AI/robotics company.”
While Tesla’s last annual or 10-K filing showed that around 95% of its revenue came from its “automotive” segment in 2022, in its third-quarter 2023 financial filing, the company described its business as “increasingly focused on products and services based on artificial intelligence, robotics and automation.”
Even on Monday morning, Musk posted a video clip on X showing the Optimus robot in development folding laundry at a table, although the robot was remote-operated and not autonomous.
Musk’s wish to control even more of Tesla will undoubtedly add to the pressure on Tesla’s board of directors in 2024.
In addition to determining appropriate CEO and director compensation, Tesla’s board is already facing some investors’ concerns over several issues.
Musk is also in the midst of a trial in Delaware over his earlier $56 billion pay package from Tesla. The unparalleled 2018 CEO compensation plan made Musk into one of the richest people on the planet.
Shareholder Richard J. Tornetta has sued Musk and Tesla, alleging the CEO’s compensation was excessive and its authorization amounted to a breach of fiduciary duty by Tesla and its board.
Musk also noted on Monday that Tesla’s board of directors is waiting to establish a new compensation plan for him until the Tornetta case is decided in the Delaware chancery court.
He wrote: “The reason for no new ‘compensation plan’ is that we are still waiting for a decision in my Delaware compensation case. The trial for that was held in 2022, but a verdict has yet to be made.”
Referring to his call for 25% voting control, he said: “If I have 25%, it means I am influential, but can be overridden if twice as many shareholders vote against me vs for me. At 15% or lower, the for/against ratio to override me makes a takeover by dubious interests too easy.”
In an earlier trial in Delaware, several Tesla board members agreed last year to pay back $735 million to the company in a settlement agreement over their own director compensation.
Bitcoin briefly dropped below the $90,000 mark on Monday, extending its slide as investors continue to dump growth oriented assets like crypto and tech stocks.
The price of the flagship cryptocurrency was last lower by 3% at $91,358.66 to start the week, according to Coin Metrics. Earlier, it fell as low as $89,259.00. Bitcoin is down 10% in the past week.
Stock Chart IconStock chart icon
Bitcoin extends its slide as growth-oriented assets continue to get hit
“The need for liquidity is caused by FX spikes because of strong end-of-year U.S. economy number, the stock market rallying strong, and there are other places money is needed in the short-term,” said James Davies, co-founder and CEO at crypto trading platform Crypto Valley Exchange. “If we want bitcoin to act like a currency, we need to accept when it does, and this is one of those times. The U.S. Dollar has gotten stronger ad everything else including bitcoin is weaker when measured in dollars.”
Investor sentiment was optimistic coming into 2025, with markets looking forward to having a pro-crypto Congress and White House. That hope had outweighed any concern about macroeconomic-related speedbumps, until last week.
Investors are now warning that the first quarter of this year could be more turbulent for crypto than previously anticipated.
Bitcoin’s price grew 120% in 2024 but is down 3% so far in the new year.
Don’t miss these cryptocurrency insights from CNBC Pro:
Health-care payments company Waystar on Monday announced a new generative artificial intelligence tool that can help hospitals quickly tackle one of their most costly and tedious responsibilities: fighting insurance denials.
Hospitals and health systems spend nearly $20 billion a year trying to overturn denied claims, according to a March report from the group purchasing organization Premier.
“We think if we can develop software that makes people’s lives better in an otherwise stressful moment of time when they’re getting health-care, then we’re doing something good,” Waystar CEO Matt Hawkins told CNBC.
Waystar’s new solution, called AltitudeCreate, uses generative AI to automatically draft appeal letters. The company said the feature could help providers drive down costs and spare them the headache of digging through complex contracts and records to put the letters together manually.
Hawkins led Waystar through its initial public offering in June, where it raised around $1 billion. The company handled more than $1.2 trillion in gross claims volume in 2023, touching about 50% of patients in the U.S.
Claim denials have become a hot-button issue across the nation following the deadly shooting of UnitedHealthcare CEO Brian Thompson in December. Americans flooded social media with posts about their frustrations and resentment toward the insurance industry, often sharing stories about their own negative experiences.
Read more CNBC reporting on AI
When a patient receives medical care in the U.S., it kicks off a notoriously complex billing process. Providers like hospitals, health systems or ambulatory care facilities submit an invoice called a claim to an insurance company, and the insurer will approve or deny the claim based on whether or not it meets the company’s criteria for reimbursement.
If a claim is denied, patients are often responsible for covering the cost out-of-pocket. More than 450 million claims are denied each year, and denial rates are rising, Waystar said.
Providers can ask insurers to reevaluate claim denials by submitting an appeal letter, but drafting these letters is a time-consuming and expensive process that doesn’t guarantee a different outcome.
Hawkins said that while there’s been a lot of discussion around claims denials recently, AltitudeCreate has been in the works at Waystar for the last six to eight months. The company announced an AI-focused partnership with Google Cloud in May, and automating claims denials was one of the 12 use cases the companies planned to explore.
Waystar has also had a denial and appeal management software module available for several years, Hawkins added.
AltitudeCreate is one tool available within a broader suite of Waystar’s AI offerings called AltitudeAI, which the company also unveiled on Monday. AltitudeCreate rolled out to organizations that are already using Waystar’s denial and appeal management software modules earlier this month at no additional cost, the company said.
Waystar plans to make the feature more broadly available in the future.
“In the face of all of this administrative waste in health-care where provider organizations are understaffed and don’t have time to even follow up on a claim when it does get denied, we’re bringing software to bear that helps to automate that experience,” Hawkins said.
Through the collaboration, General Catalyst portfolio companies will use AWS’ services to build and roll out AI tools for health systems more quickly. Aidoc, which applies AI to medical imaging, and Commure, which automates provider workflows with AI, will be the first two companies to participate.
No financial terms were disclosed in the announcement.
“Without a strong partner like Amazon and AWS to stand alongside them, to co-develop and support these companies … it’s not going to move as fast as we hope,” Chris Bischoff, head of global health-care investing at General Catalyst, told CNBC in an interview.
Health systems are strained in the U.S., with staff burnout, growing labor shortages and razor-thin margins. These challenges often seem enticing for enterprising tech startups to tackle, especially as the multi-trillion dollar health-care industry dangles the prospect of large financial returns.
Hospitals operate in a complex, technology-weary and highly-regulated sector that can be difficult for startups to break into. General Catalyst is hoping to help its companies fast-track the development and go-to-market process by leveraging resources like computing power from AWS.
Read more CNBC reporting on AI
General Catalyst is no stranger to taking big swings in health-care.
The firm has closed more than 60 digital health deals since 2020, behind only Gaingels and Alumni Ventures, according to a December report from PitchBook. Last January, General Catalyst shocked the industry by announcing that its new business, the Health Assurance Transformation Company, planned to acquire an Ohio-based health system – an unprecedented move in venture capital.
General Catalyst’s “deep understanding” of health systems’ financial and operating realities made it an attractive partner for AWS, Dan Sheeran, AWS’ general manager of Healthcare & Life Science, told CNBC. Sheeran and Bischoff began outlining the collaboration between the two groups after meeting in London around nine months ago.
AWS also has an established presence in the health-care sector. The company offers more health- and life-sciences-specific services than any other cloud provider, according to a release, and it inked other high-profile AI partnerships with GE HealthCare, Philips and others last year.
The partnership between General Catalyst and AWS will stretch over several years, but new tools from Aidoc and Commure are coming in 2025. Aidoc is exploring how it can use the cloud to tap data modalities across pathology, cardiology, genomics and other molecular information, for instance.
Aidoc and Commure were selected to kick off the collaboration because they have both established a product-market fit, are operational and are focused on issues that are a high priority for AWS customers.
“GC has spent a lot of time thinking about how health systems can transform themselves, and we recognize that it’s not going to be through 1,000 companies, and we need solutions that are really enterprise grade,” Bischoff said. “Amazon shares the same vision, so we are starting with these two.”
Though the partnership between General Catalyst and AWS is still in its early days, the organizations said they believe it will help serve as a way to meet the market’s growing demand for new solutions.
“Health system leaders who want to realize the benefits of AI now have an easier way to accomplish that,” Sheeran said.